PUT - SPRINTER OPEN END - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 05:31:02 26/06/2024 pm IST | ||
| 2.81 EUR | -0.35% |
|
| Current month | -1.40% | ||
| 3 months | +49.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 2.81 | -0.35% |
| 25/24/25 | 2.82 | +0.71% |
| 24/24/24 | 2.8 | -2.78% |
| 21/24/21 | 2.88 | -1.71% |
| 20/24/20 | 2.93 | +1.38% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 05:31 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU3G5L |
| ISIN | DE000VU3G5L5 |
| Date issued | 10/02/2023 |
| Strike | 72.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.96 € |
|---|---|
| Lowest since issue | 0.04 € |
| Spread | 0.02 € |
| Spread % | 0.71% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.19
USD
Average target price
53.19
USD
Spread / Average Target
+26.08%
- Stock Market
- Certificates
- Certificat
